Video

Elizabeth Blasiak Discusses the ONS Congress

Author(s):

Elizabeth Blasiak, RN, MSN

Elizabeth Blasiak on the Significance of the ONS Congress

Elizabeth Blasiak, RN, MSN, OCN®, Medical Oncology, Smilow Cancer Hospital at Yale New Haven Hospital, New Haven, CT on the significance of the ONS congress.

Related Videos
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Ana Christina Garrido-Castro, MD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Jean-Marc Classe, MD, PhD, Nantes Université
Bradley McGregor, MD
Kevin Kalinsky, MD, MS
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Arndt Vogel, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Related Content
Erin Frances Cobain, MD
June 8th 2024

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

Sundar Jagannath, MBBS, director, the Center of Excellence for Multiple Myeloma, professor, Medicine, Mount Sinai Tisch Cancer Institute
June 7th 2024

Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma

Mansoor Raza Mirza, MD
June 7th 2024

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

Fernando Cotait Maluf, MD
June 7th 2024

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

Charlene Mantia, MD, of Dana-Farber Cancer Institute
June 6th 2024

Nivolumab/Cabozantinib Combination Prolongs Treatment-Free Survival in Advanced RCC

Roger Li, MD
June 6th 2024

High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab